Owen Mumford Publishes Annual Responsible Action Report

Highlighting B Corp Certification and Science-Based Targets Milestones

Owen Mumford (medical device manufactuer) has published its latest annual Responsible Action Report, highlighting progress and achievements in 2021 including its recent B Corp certification and alignment with the Science Based Targets initiative (SBTi) to achieve net zero carbon emissions by 2045, as the company continues to strengthen its sustainability strategy and future-proof its operations.

In June 2021, Owen Mumford was awarded B Corp certification in recognition of its commitment to corporate social responsibility regarding the environment, governance, community engagement, employee support, and customer stewardship. The certification makes Owen Mumford one of the first medical device manufacturers in the world to achieve this, joining over 4,000 global businesses working towards improving their benchmarks and raising standards across all industries.

Sustainability continues to be a key area of focus for Owen Mumford, demonstrated through commitments towards emissions reduction targets with the SBTi. The company has set a target to reach a 50% reduction in carbon emissions by 2030 and become net zero by 2045. Owen Mumford has also joined the Race to Zero movement in 2021, a collaboration of leading companies across the globe supporting efforts to achieve zero carbon recovery.

The report charts the organization’s progress against its chosen United Nations Sustainable Development Goals (SDGs), covering a variety of well-being, infrastructural, and responsible consumption themes. Highlights for 2021 include continued support for the promotion of women in STEM subjects through local collaboration with schools and colleges, to continued evaluation of its logistics output to reduce carbon emissions and lead times to customers. Other initiatives support the company’s commitment to its associates, customers, products, and the planet.

“This past year has been challenging for us all as we entered the second year of the pandemic. Thankfully, 2021 marked a year of growth, action and above all else, resilience for Owen Mumford. Whether achieving B Corp certification, committing to reducing our emissions footprint, or continuing investment in more sustainable products, we have a great deal to be proud of,” said Jarl Severn, CEO of Owen Mumford.

He concluded, “Our goal is to continue with a positive influence on the medical device industry, leading by example on how products should be responsibly made, companies should be ethically run, and futures should be protected. I hope that the hard work and commitment from everyone at Owen Mumford encourages other companies and individuals to implement their own action plans and work towards a better future for everyone.”

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.